Magnetic Resonance
MRI for Alzheimer’s disease
MRI for Alzheimer’s disease diagnosis and monitoring
The demand for MRI in relation to Alzheimer’s disease is rising. More than 55 million people worldwide are living with Alzheimer’s disease, and this number is expected to increase to 139 million by 2050 [1]. Recent advancements in treatment require ongoing MRI scans to monitor patients and assess for possible Alzheimer’s-related imaging abnormalities (ARIA) [2]. At least four additional MRI scans are required in the first 12 months of treatment for safety monitoring [2,3]. Challenges are now emerging related to access to MRI equipment and staff shortages. Philips is dedicated to supporting earlier, faster and more precise diagnosis and treatment monitoring of Alzheimer’s disease.
Demonstrated results in Alzheimer’s disease
Up to 3x
faster imaging
to help reduce exam time and increase productivity [4].
Read more0-click
workflow for quantitative report generation
with Smart Reading. It enhances efficiency and ensures compliance with the latest clinical guidelines through advanced cloud processing, boosting clinical outcomes [5].
Read more<1 min
patient set-up
for routine exams can be done in under one minute, even by less experienced operators [6].
Read more
Fast and streamlined MRI workflow from imaging to quantitative reporting
Our aim is to enable fast, high-quality brain MR examinations for Alzheimer’s disease through our portfolio of AI-enabled MRI scanners, standardized and efficient neuroimaging protocols and integrated quantitative reporting. Our MR solutions are designed to support the detection and characterization of Alzheimer’s-related imaging findings, including regional brain atrophy and treatment-related abnormalities such as ARIA-E and ARIA-H. They also support longitudinal monitoring of disease progression and therapy safety while optimizing workflow efficiency and maintaining high diagnostic quality.
MRI capabilities for Alzheimer’s disease diagnosis and ARIA monitoring
- Increase access to care with helium-free operating MR systems for flexible siting and uninterrupted operations
- Transform productivity with AI-enabled tools that deliver fast, high-quality imaging
- Seamlessly integrated AI-powered quantitative reports for Alzheimer’s diagnosis and treatment monitoring, including monitoring of treatment-related imaging findings such as ARIA-E and ARIA-H
- A comfortable and engaging patient experience by providing dynamic lighting, sound, video and audio-guidance
Streamlined and AI-enabled workflow
- SmartExam automates protocol selection and scan setup to reduce variability and operator effort
- SmartSpeed Precise accelerates imaging with dual AI reconstruction while maintaining high-quality results
- Smart Reading delivers seamless [7] integration of validated AI cloud-based reading and quantitative reporting tools for Alzheimer’s diagnosis and monitoring on the MR console
- Ambient Experience & In-bore Connect engage patients with immersive lighting, sound, visuals and in-bore interaction to support patient comfort and compliance
- AutoVoice: automated patient coaching
Image gallery
- ASNR-recommended consensus protocols for imaging of Alzheimer’s Disease Anti-Amyloid Immunotherapies (ARIA) on Elition 3.0T X with SmartSpeed [8]
- T2w FLAIR, 0.65 x 1.1 x 4.0 mm, 2:08 min
- T2* FFE, 0.9 x 1.1 x 4.0 mm, 1:33 min
- DWI b0, 1.6 x 2.0 x 4.0 mm, 0:36 min
- DWI b1000, 1.6 x 2.0 x 4.0 mm, 0:36 min
- 3D FLAIR, 1.1 x 1.1 x 1.1 mm, 2:58 min
- 3D T1w TFE (MPRAGE), 1.0 x 1.0 x 1.0 mm, 2:23 min
- 3D SWI (Magnitude), 0.6 x 0.6 x 2.0 mm, 2:40 min
- 3D SWI (Phase), 0.6 x 0.6 x 2.0 mm, 2:40 min
- ASNR-recommended consensus protocols for imaging of Alzheimer’s Disease Anti-Amyloid Immunotherapies (ARIA) on MR 5300 with SmartSpeed [8]
- T2w FLAIR, 0.9 x 1.1 x 4.0 mm, 3:18 min
- T2* FFE, 0.9 x 1.1 x 4.0 mm, 2:47 min
- DWI b0, 1.6 x 2.0 x 4.0 mm, 0:53 min
- DWI b1000, 1.6 x 2.0 x 4.0 mm, 0:53 min
- 3D FLAIR, 1.2 x 1.2 x 1.2 mm, 3:32 min
- 3D T1w TFE (MPRAGE), 1.05 x 1.05 x 1.1 mm, 2:56 min
- 3D SWI (Magnitude), 0.85 x 0.85 x 2.0 mm, 3:25 min
- 3D SWI (Phase), 0.85 x 0.85 x 2.0 mm, 3:25 min
- ASNR minimal required imaging protocol for imaging of Alzheimer’s Disease Anti-Amyloid Immunotherapies (ARIA) [8] plus a 3D T1w TFE on Elition 3.0T X with SmartSpeed in 7:16 min
- T2w FLAIR, 0.6 x 1.1 x 4.0 mm, 2:40 min
- T2* FFE, 0.9 x 1.1 x 4.0 mm, 1:34 min
- DWI, 1.3 x 1.3 x 4.0 mm, 36 sec
- 3D T1w TFE, 1.0 x 1.0 x 1.0 mm, 2:26 min
Featured solutions Alzheimer’s disease
Accelerate your Alzheimer’s protocols with Dual AI
Transform brain MRI for Alzheimer’s patients by enabling significantly faster and sharper imaging with SmartSpeed Precise. With scan times up to three times faster [4] and spatial resolution improved by up to 80% [9], it supports efficient acquisition of high-quality images. This supports clinicians in better detecting subtle Alzheimer’s-related changes while optimizing productivity.
Seamlessly integrated reading quantitative reporting tools
Smart Reading is the industry‘s first seamless [7] integration of validated AI cloud-based reading and quantitative reporting tools on the MR console for efficiency and improved outcomes. It enables real-time AI-driven report generation, optimized protocol settings and immediate scan quality feedback, all tailored for specific clinical needs like chronic neurological diseases including Alzheimer’s disease.
Automated quantitative processing to assist with Alzheimer’s diagnosis
With NeuroQuant® you can automatically segment, quantify and compare brain structure volume for neurodegenerative diseases like Alzheimer’s. It’s designed to deliver objective, volumetric data and color-coded brain structure analysis to increase diagnostic accuracy and reduce variability between readers.
Our big goal is to do the exam right the very first time. Diagnosing Alzheimer's disease early, has a tremendous impact on the patient's trajectory of disease, which is why it's so important.
Dr. Suzie Bash
Neuroradiologist and Medical Director
Frequently asked questions
Footnotes
- Dementia Statistics Hub, prevalence and incidence: (Accessed May 2025)
- Padda IS, Parmar M. Aducanumab. StatPearls Publishing; 2026 Jan. https://www.ncbi.nlm.nih.gov/books/NBK573062/.
- https://www.leqembi.com/-/media/Files/Leqembi/Prescribing-Information.pdf.
- Compared to Philips SENSE/ C-SENSE imaging.
- Workflow refers to steps after completion of data-acquisition to AI processing. No additional user-interaction is required to send data to the External application cloud and to receive reports in PACS.
- < 1 min patient set-up for routine exams, based on in-house testing. Results may vary.
- Seamless indicates the workflow is an automatically enabled post-processing step in MR-console. Validation of the AI applications is done by the 3rd party and not by Philips.
- Cogswell et al., AJNR 2022,43(9)E19-E35;DOI: https://doi.org/10.3174/ajnr.A7586.
- Compared to Philips SENSE/ C-SENSE imaging.
- Chiara, M., Francesca, T., Andrea, R. et al. MRI in the Clinical Management of Alzheimer’s Disease: from Early Detection To Therapy Guidance. Curr Radiol Rep 13, 4 (2025): https://doi.org/10.1007/s40134-025-00435-0.
- Kakeda S, Miki Y, Kudo K, Mori H, et al. Practical Brain MRI Guidelines for Anti-Aβ Antibody Treatment in Early Symptomatic Alzheimer's Disease. Magn Reson Med Sci. 2025 Nov 20;24(4):2025-1000: https://pubmed.ncbi.nlm.nih.gov/40189284/.
- Reijner, N., Frigerio, I., Bouwman, M.M.A. et al. Clinical phenotypes of Alzheimer’s disease: investigating atrophy patterns and their pathological correlates. Alz Res Therapy 17, 93 (2025). https://doi.org/10.1186/s13195-025-01727-5.
- Frisoni GB, Fox NC, Jack CR Jr, Scheltens P, Thompson PM. The clinical use of structural MRI in Alzheimer disease. Nat Rev Neurol. 2010 Feb;6(2):67-77: https://www.nature.com/articles/nrneurol.2009.215.
- De Francesco, S., Crema, C., Archetti, D. et al. Differential diagnosis of neurodegenerative dementias with the explainable MRI based machine learning algorithm MUQUBIA. Sci Rep 13, 17355 (2023). https://doi.org/10.1038/s41598-023-43706-6.
- Persson K, Braekhus A, Selbaek G, et al. Comparison of automated volumetry of the hippocampus using NeuroQuant® and visual assessment of the medial temporal lobe in Alzheimer’s disease. Acta Radiol. 2018;59(7):886-893: https://journals.sagepub.com/doi/10.1177/0284185117743778.
- Persson K, Brækhus A, Selbæk G, et al. Diagnostic validity of regional brain volumes using NeuroQuant compared to visual rating scales in dementia. Brain Behav. 2024;14(2):e3397: https://onlinelibrary.wiley.com/doi/10.1002/brb3.3397.
- Essien M, Kluger B, Liu W, et al. Automated hippocampal volumetry versus structured visual rating scales for Alzheimer’s disease, mild cognitive impairment, and subjective cognitive decline. AJNR Am J Neuroradiol. 2023;44(12):1411–1417.
- Hampel H, Elhage A, Cho M, Apostolova LG, Nicoll JAR, Atri A. Amyloid-related imaging abnormalities (ARIA): radiological, biological and clinical characteristics. Brain. 2023 Nov 2;146(11):4414-4424. doi: 10.1093/brain/awad188. PMID: 37280110; PMCID: PMC10629981. https://academic.oup.com/brain/article/146/11/4414/7191051
Disclaimer
Helium-free operations. 7 liters of helium is permanently enclosed in the cryogenic circuit.
NeuroQuant® is a trademark of CorTechs Labs, Inc. Not available for sale in all countries. Please check for availability in specific countries.